Low-cost detection test for cancer

December 15, 2023

Worldwide each year, 19.3 million people are diagnosed with cancer and the numbers are growing. Nearly 1 in 6 deaths is caused by cancer. The need to expedite diagnostics is vital. As more and curative treatments options are available the earlier cancer is diagnosed and the negative impact on quality of life is reduced. We are in need of a multi cancer test and OncoInv offers you one.

OncoSeek® is a low-cost detection test for cancer

OncoSeek® uses a combination of a selected number of specific plasma tumor markers, a new multivariate algorithm, big data and Machine Learning. It performs screening for the most common cancers, calculates the cancer risk score (CRS), and traces the cancer tissue of origin (TOO). It’s scientifically validated and CE-certified. OncoSeek can be easily implemented as it uses existing medical infrastructure.

OncoSeek® can be used anywhere in the world by medical organisations who provide health services to the public. Laboratory services are included when needed.

If your organisation is interested in OncoSeek® we invite you to contact us at info@oncoinv.org

More news

OncoInv explores personalization in multi-cancer detection at international course in Madrid

September 23rd, 2026

On September 16th, HM Hospitales hosted the 4th International Course on Hyper-Early Cancer Diagnosis in Oncology for physicians, coordinated by Dr. Antonio Cubillo and Dra. Paloma Peinado. The course convened more than 200 participants in person and online,....

Read more
Multi-cancer detection beyond the test: reflections from Barcelona

April 16th, 2026

What does it take to move a promising technology from research into responsible clinical practice? That was a central question at OncoInv's expert meeting at Barcelona Health Hub..

Read more
OncoInv convenes second expert meeting on multi-cancer detection in Barcelona

March 26th, 2026

Following the expert meeting in Madrid in February, OncoInv continues the conversation on multi-cancer detection (MCD) with a second session at Barcelona Health Hub.  

Read more